Although SBG in Polyethylene containers induced improved wound healing as compared to vehicle control, the difference did not reach statistical significance. All animals treated with SBG showed statistical significant improved wound healing at one or more time points when compared to non-treated animals, but only SBG batch 252-7 stored in Polycarbonate containers showed statistical significant difference at all time points.
These results conclude the efforts to understand what happened in the failed phase III study. The company is now focused on the commercialization of the SBG technology with the main focus on topical wound healing. In a resent strategy discussion among the Board of Directors it became clear that most likely the first product application will be classified as a medical device. Discussions with potential partners are ongoing.
Please find enclosed the complete update including the graphs from the study.
Biotec Pharmacon receives promising results from animal study of SBG which confirms initial findings announced in the Q2 Report
Biotec Pharmacon has received a preliminary report of the results from the animal study of SBG (soluble beta glucan) in diabetic mice. The results confirm the initial findings presented in the company’s financial report for the second quarter 2010, which stated that the failure of the phase III study of SBG was due to product instability in Polyethylene containers. The study, performed by Cica Biomedical Ltd, showed that SBG stored in Polycarbonate containers (252-7) induced statistically significant improved wound closure both when compared to non-treated wounds and vehicle control wounds, as opposed to Polyethylene containers (IB274) that were used in the phase III study.
